Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 11/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974153 | 1.00 | HDAC4 (0.51) | HDAC4POLBHTTRAB9AHSD11B1 | |
| SCHEMBL6406684 | 1.00 | HDAC4 (0.51) | HDAC4POLBHTTRAB9AHSD11B1 | |
| SCHEMBL4969359 | 1.00 | HDAC4 (0.51) | HDAC4POLBHTTRAB9AHSD11B1 | |
| SCHEMBL6406617 | 0.85 | HDAC4 (0.52) | HDAC4HSD11B1ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL6408662 | 0.82 | HDAC4 (0.52) | HDAC4HTTHSD11B1ALDH1A1LMNA | |
| SCHEMBL4961970 | 0.80 | POLB (0.57) | HDAC4POLBRAB9AHSD11B1ALDH1A1 | |
| SCHEMBL4965692 | 0.77 | P2RX7 (0.50) | HDAC4HSD11B1ALDH1A1 | |
| SCHEMBL6379903 | 0.76 | POLB (0.64) | POLBHTTRAB9AALDH1A1CASP1 | |
| SCHEMBL6379897 | 0.76 | POLB (0.64) | POLBHTTRAB9AALDH1A1CASP1 | |
| SCHEMBL6379907 | 0.76 | POLB (0.64) | POLBHTTRAB9AALDH1A1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | claimed |
| EP-1773780-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1773780-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006012227-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HDAC4 1710/4885POLB 2445/4885HTT 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.